JP5689117B2 - 心不全を防止及び治療するための組成物及び方法 - Google Patents
心不全を防止及び治療するための組成物及び方法 Download PDFInfo
- Publication number
- JP5689117B2 JP5689117B2 JP2012514548A JP2012514548A JP5689117B2 JP 5689117 B2 JP5689117 B2 JP 5689117B2 JP 2012514548 A JP2012514548 A JP 2012514548A JP 2012514548 A JP2012514548 A JP 2012514548A JP 5689117 B2 JP5689117 B2 JP 5689117B2
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- administration
- heart failure
- composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010019280 Heart failures Diseases 0.000 title claims description 99
- 239000000203 mixture Substances 0.000 title claims description 70
- 238000000034 method Methods 0.000 title description 28
- 150000001875 compounds Chemical class 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 50
- 239000000284 extract Substances 0.000 claims description 46
- 229940079593 drug Drugs 0.000 claims description 24
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 21
- 208000010125 myocardial infarction Diseases 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 241000220259 Raphanus Species 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 235000004032 Centella asiatica Nutrition 0.000 claims description 7
- 244000146462 Centella asiatica Species 0.000 claims description 7
- 210000004351 coronary vessel Anatomy 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 208000009525 Myocarditis Diseases 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010013654 Drug abuse Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 3
- 208000024799 Thyroid disease Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 3
- 206010001584 alcohol abuse Diseases 0.000 claims description 3
- 208000025746 alcohol use disease Diseases 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 231100000457 cardiotoxic Toxicity 0.000 claims description 3
- 230000001451 cardiotoxic effect Effects 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- 230000009395 genetic defect Effects 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 235000003642 hunger Nutrition 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000008494 pericarditis Diseases 0.000 claims description 3
- 230000037351 starvation Effects 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 208000021510 thyroid gland disease Diseases 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 2
- 235000009709 Geum japonicum Nutrition 0.000 claims 2
- 241001618015 Geum japonicum Species 0.000 claims 2
- 229960005156 digoxin Drugs 0.000 claims 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 2
- 238000007910 systemic administration Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 description 28
- 235000011034 Rubus glaucus Nutrition 0.000 description 26
- 235000009122 Rubus idaeus Nutrition 0.000 description 26
- 239000002253 acid Substances 0.000 description 26
- 210000002216 heart Anatomy 0.000 description 26
- OXVUXGFZHDKYLS-BLIWDXROSA-N Tormentic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-BLIWDXROSA-N 0.000 description 24
- 235000013824 polyphenols Nutrition 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 244000235659 Rubus idaeus Species 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- -1 triterpenoid polyphenol Chemical class 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 241001092459 Rubus Species 0.000 description 14
- 208000029078 coronary artery disease Diseases 0.000 description 13
- VULLSLYDWNGNKZ-UHFFFAOYSA-N 12319Tetrahydroxyurs-12-en-28-oic acid Natural products OC1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C VULLSLYDWNGNKZ-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OXVUXGFZHDKYLS-UHFFFAOYSA-N Jacarandic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C OXVUXGFZHDKYLS-UHFFFAOYSA-N 0.000 description 12
- 210000004413 cardiac myocyte Anatomy 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 description 11
- 230000002861 ventricular Effects 0.000 description 11
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 10
- 241000219492 Quercus Species 0.000 description 10
- 240000007651 Rubus glaucus Species 0.000 description 10
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 10
- 229940022757 asiaticoside Drugs 0.000 description 10
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 150000003648 triterpenes Chemical class 0.000 description 10
- BZIGXGRVQSNLNL-UHFFFAOYSA-N Gemin A Natural products Oc1ccc(C(=O)OC2C(OC(=O)c3cc(O)c(O)c(Oc4c(O)c(O)c(O)cc4C(=O)OC5OC6COC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OC6C9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)OC59)c3)OC%12COC(=O)c%13cc(O)c(O)c(O)c%13c%14c(O)c(O)c(O)cc%14C(=O)OC%12C2OC(=O)c%15cc(O)c(O)c(O)c%15)c(O)c1O BZIGXGRVQSNLNL-UHFFFAOYSA-N 0.000 description 9
- ODXMIHPUPFEYDB-HISCDKSNSA-N Gemin A Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@@H]2[C@H]([C@@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@H]3O[C@@H]2OC(=O)C=2C=C(OC=3C(=CC(O)=C(O)C=3O)C(=O)O[C@@H]3[C@@H]4OC(=O)C5=CC(O)=C(O)C(O)=C5C5=C(O)C(O)=C(O)C=C5C(=O)O[C@H]4[C@@H]4OC(=O)C5=CC(O)=C(O)C(O)=C5C5=C(O)C(O)=C(O)C=C5C(=O)OC[C@H]4O3)C(O)=C(O)C=2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 ODXMIHPUPFEYDB-HISCDKSNSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 8
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 8
- 229940011658 asiatic acid Drugs 0.000 description 8
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 235000004789 Rosa xanthina Nutrition 0.000 description 7
- 241000220222 Rosaceae Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 6
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 6
- 229920002079 Ellagic acid Polymers 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960002852 ellagic acid Drugs 0.000 description 6
- 235000004132 ellagic acid Nutrition 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 6
- 235000021508 Coleus Nutrition 0.000 description 5
- 244000061182 Coleus blumei Species 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 235000016623 Fragaria vesca Nutrition 0.000 description 5
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 5
- 241000219422 Urtica Species 0.000 description 5
- 235000009108 Urtica dioica Nutrition 0.000 description 5
- 230000008081 blood perfusion Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000401 methanolic extract Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 244000296825 Amygdalus nana Species 0.000 description 4
- 235000003840 Amygdalus nana Nutrition 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 241000132536 Cirsium Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 244000061508 Eriobotrya japonica Species 0.000 description 4
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 4
- 240000009088 Fragaria x ananassa Species 0.000 description 4
- 241000209035 Ilex Species 0.000 description 4
- 235000003325 Ilex Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000011432 Prunus Nutrition 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000009194 climbing Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000002592 echocardiography Methods 0.000 description 4
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 235000014774 prunus Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940096998 ursolic acid Drugs 0.000 description 4
- 241001278836 Agrimonia pilosa Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000407877 Combretum Species 0.000 description 3
- 206010019842 Hepatomegaly Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000207923 Lamiaceae Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001043741 Musanga cecropioides Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000155437 Raphanus sativus var. niger Species 0.000 description 3
- 241000589180 Rhizobium Species 0.000 description 3
- 241001072909 Salvia Species 0.000 description 3
- 235000017276 Salvia Nutrition 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- HFGSQOYIOKBQOW-PUNAAJGVSA-N (1S,2R,4aS,6aR,6aS,6bR,8aR,10R,12aR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid Chemical compound C1C(O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C HFGSQOYIOKBQOW-PUNAAJGVSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- HNRMPXKDFBEGFZ-UHFFFAOYSA-N 2,2-dimethylbutane Chemical compound CCC(C)(C)C HNRMPXKDFBEGFZ-UHFFFAOYSA-N 0.000 description 2
- GKRMBTQHEPCVKU-UHFFFAOYSA-N 28-dioic acid Natural products OC1C(O)C(OC2C(C(O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(CCC2(C)C3(C)CCC4C5(C)C(O)=O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O GKRMBTQHEPCVKU-UHFFFAOYSA-N 0.000 description 2
- 241000975823 Acaena Species 0.000 description 2
- 241000208140 Acer Species 0.000 description 2
- 241001292340 Adenandra Species 0.000 description 2
- 244000277177 Anchusa azurea Species 0.000 description 2
- 235000017106 Anchusa azurea Nutrition 0.000 description 2
- 241000130781 Arnebia Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241001249699 Capitata Species 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 241001479486 Desfontainia spinosa Species 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001022534 Ellipticus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- BBVSUTXRTIIZIX-STRNLIFHSA-N Gemin B Natural products O=C(O[C@@H]1O[C@H](CO)[C@H](O)[C@@H]2OC(=O)c3c(c(O)c(O)c(O)c3)-c3c(O)c(O)c(O)cc3C(=O)O[C@H]12)c1c(Oc2c(O)c(O)cc(C(=O)O[C@H]3[C@@H](OC(=O)c4cc(O)c(O)c(O)c4)[C@H](OC(=O)c4cc(O)c(O)c(O)c4)[C@H]4OC(=O)c5c(c(O)c(O)c(O)c5)-c5c(O)c(O)c(O)cc5C(=O)OC[C@H]4O3)c2)c(O)c(O)c(O)c1 BBVSUTXRTIIZIX-STRNLIFHSA-N 0.000 description 2
- YKLNPEYKZHHXKJ-QRFSJKBVSA-N Gemin C Natural products O=C(O[C@H]1O[C@H]2[C@@H](OC(=O)c3c(c(O)c(O)c(O)c3)-c3c(O)c(O)c(O)cc3C(=O)OC2)[C@@H]2OC(=O)c3c(c(O)c(O)c(O)c3)-c3c(O)c(O)c(O)cc3C(=O)O[C@H]12)c1c(Oc2c(O)c(O)cc(C(=O)O[C@H]3[C@H](OC(=O)c4cc(O)c(O)c(O)c4)[C@H](OC(=O)c4cc(O)c(O)c(O)c4)[C@@H](O)[C@H](CO)O3)c2)c(O)c(O)c(O)c1 YKLNPEYKZHHXKJ-QRFSJKBVSA-N 0.000 description 2
- XKVYZLLWKHGKMT-BEJOYRPXSA-N Gemin D Natural products O([C@@H]([C@@H](O)C=O)[C@@H]1[C@@H](O)COC(=O)c2c(c(O)c(O)c(O)c2)-c2c(O)c(O)c(O)cc2C(=O)O1)C(=O)c1cc(O)c(O)c(O)c1 XKVYZLLWKHGKMT-BEJOYRPXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000167880 Hirundinidae Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 240000000786 Margyricarpus pinnatus Species 0.000 description 2
- 235000010838 Margyricarpus pinnatus Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000003805 Musa ABB Group Nutrition 0.000 description 2
- 241000629535 Oresbius Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000015266 Plantago major Nutrition 0.000 description 2
- 244000179560 Prunella vulgaris Species 0.000 description 2
- 235000010674 Prunella vulgaris Nutrition 0.000 description 2
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 2
- 241001632927 Rosa taiwanensis Species 0.000 description 2
- 241000975783 Sarcopoterium spinosum Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 241000246358 Thymus Species 0.000 description 2
- 241001403962 Thymus mongolicus Species 0.000 description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- SWRFKGRMQVLMKA-UHFFFAOYSA-N casuarictin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC2C3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC3C3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OCC3O2)=C1 SWRFKGRMQVLMKA-UHFFFAOYSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZWKOPCKVJMISSO-UHFFFAOYSA-N gemin E Natural products OC1C2OC(=O)C3=C1C(=O)C(O)(O)C4(O)Oc5c(O)c(O)cc(C(=O)OC2C6OC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OCC6OC(=O)c9cc(O)c(O)c(O)c9)c5C34 ZWKOPCKVJMISSO-UHFFFAOYSA-N 0.000 description 2
- NIGWBANYTBFQGE-UHFFFAOYSA-N gemin F Natural products OC1OC(COC(=O)C=Cc2ccc(O)c(O)c2)C(O)C3OC(=O)c4cc(O)c(O)c(O)c4c5c(O)c(O)c(O)cc5C(=O)OC13 NIGWBANYTBFQGE-UHFFFAOYSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 229920001461 hydrolysable tannin Polymers 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 2
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 2
- 229940011656 madecassic acid Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000004810 partition chromatography Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229930195215 pungen Natural products 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 239000001585 thymus vulgaris Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- MLKQAGPAYHTNQQ-UHFFFAOYSA-N tormentic acid glucosyl ester Natural products C1CC(C2(CCC3C(C)(C)C(O)C(O)CC3(C)C2CC=2)C)(C)C=2C2C(O)(C)C(C)CCC21C(=O)OC1OC(CO)C(O)C(O)C1O MLKQAGPAYHTNQQ-UHFFFAOYSA-N 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WKKBYJLXSKPKSC-JVJIQXRHSA-N 19alpha-hydroxyasiatic acid-28-O-beta-D-glucopyrannoside Chemical compound O=C([C@]12CC[C@H]([C@@]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)(C)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WKKBYJLXSKPKSC-JVJIQXRHSA-N 0.000 description 1
- 241000770193 Acaena magellanica Species 0.000 description 1
- 241001297833 Acanthochlamys bracteata Species 0.000 description 1
- 235000000641 Agrimonia pilosa Nutrition 0.000 description 1
- 235000017847 Anchusa officinalis Nutrition 0.000 description 1
- 244000242323 Anchusa officinalis Species 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 241000169673 Aphloia Species 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000004972 Bergenia crassifolia Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241001279228 Campylotropis hirtella Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 244000097582 Cecropia peltata Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241001311587 Clematoclethra Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 241001507946 Cotoneaster Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241001314984 Cyphotheca Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001479540 Echium vulgare Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000918780 Eriope Species 0.000 description 1
- 241000238558 Eucarida Species 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229930182603 Euscaphic acid Natural products 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010052359 Gingival abscess Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 241000267377 Ilex godajam Species 0.000 description 1
- 241000519740 Ilex rotunda Species 0.000 description 1
- 235000008702 Ilex rotunda Nutrition 0.000 description 1
- 241001183967 Isodon Species 0.000 description 1
- 241001102691 Ixora Species 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000729196 Lycopus lucidus Species 0.000 description 1
- 235000005058 Madhuca longifolia Nutrition 0.000 description 1
- 240000004212 Madhuca longifolia Species 0.000 description 1
- 241000219171 Malpighiales Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000091577 Mexicana Species 0.000 description 1
- 241000069154 Miconia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 241001043774 Musanga Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000909583 Ocotea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241001303775 Phlomis Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000975797 Polylepis Species 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 235000009073 Quercus cerris Nutrition 0.000 description 1
- 240000007274 Quercus cerris Species 0.000 description 1
- 241001480058 Quercus glauca Species 0.000 description 1
- 235000011471 Quercus robur Nutrition 0.000 description 1
- 240000009089 Quercus robur Species 0.000 description 1
- 241000593917 Quercus virginiana Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 235000016607 Rosa bella Nutrition 0.000 description 1
- 241000914162 Rosa bella Species 0.000 description 1
- 240000002547 Rosa roxburghii Species 0.000 description 1
- 235000000640 Rosa roxburghii Nutrition 0.000 description 1
- 241001485737 Rosa transmorrisonensis Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 235000005247 Rumex japonicus Nutrition 0.000 description 1
- 244000189123 Rumex japonicus Species 0.000 description 1
- 241000081623 Sabia parviflora Species 0.000 description 1
- 241000687924 Salvia trijuga Species 0.000 description 1
- 235000017566 Salvia trijuga Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000256103 Simuliidae Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000002173 Symplocos chinensis Nutrition 0.000 description 1
- 240000006507 Symplocos chinensis Species 0.000 description 1
- 241001414989 Thysanoptera Species 0.000 description 1
- 241000124333 Tiarella Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000777020 Tristania Species 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 240000001519 Verbena officinalis Species 0.000 description 1
- 235000018718 Verbena officinalis Nutrition 0.000 description 1
- 240000000059 Vitex cofassus Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000269959 Xiphias gladius Species 0.000 description 1
- 241000255737 Zophobas atratus Species 0.000 description 1
- MLKQAGPAYHTNQQ-FUZXVMJXSA-N [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,11R,12aR,14bS)-1,10,11-trihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate Chemical compound O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2 MLKQAGPAYHTNQQ-FUZXVMJXSA-N 0.000 description 1
- MLKQAGPAYHTNQQ-BRDPIYJESA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1r,2r,4as,6ar,6as,6br,8ar,10r,11r,12ar,14bs)-1,10,11-trihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate Chemical compound O=C([C@]12CC[C@H]([C@@]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)(C)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MLKQAGPAYHTNQQ-BRDPIYJESA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 101150045355 akt1 gene Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 235000009347 chasteberry Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000004185 countercurrent chromatography Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229910001254 electrum Inorganic materials 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- OXVUXGFZHDKYLS-QUFHAEKXSA-N euscaphic acid Chemical compound C1[C@@H](O)[C@@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-QUFHAEKXSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- XXOYNJXVWVNOOJ-UHFFFAOYSA-N fenuron Chemical compound CN(C)C(=O)NC1=CC=CC=C1 XXOYNJXVWVNOOJ-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 208000014987 limb edema Diseases 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- WKKBYJLXSKPKSC-UHFFFAOYSA-N niga-ichigoside F2 Natural products C1CC(C2(CCC3C(C)(CO)C(O)C(O)CC3(C)C2CC=2)C)(C)C=2C2C(O)(C)C(C)CCC21C(=O)OC1OC(CO)C(O)C(O)C1O WKKBYJLXSKPKSC-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229930185113 potentilin Natural products 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- QGTBWTXRSOKBBE-QZIYNGKJSA-N rosamultin Natural products CC1(C)[C@@H](O)[C@H](O)C[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2CC=C4[C@@H]5[C@@](C)(O)C(C)(C)CC[C@@]5(CC[C@@]34C)C(=O)O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O QGTBWTXRSOKBBE-QZIYNGKJSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000021335 sword fish Nutrition 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003505 terpenes Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 125000003523 triterpene group Chemical group 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18670909P | 2009-06-12 | 2009-06-12 | |
| US61/186,709 | 2009-06-12 | ||
| US18790509P | 2009-06-17 | 2009-06-17 | |
| US61/187,905 | 2009-06-17 | ||
| PCT/IB2010/001410 WO2010143058A1 (en) | 2009-06-12 | 2010-06-11 | Compositions and methods for the prevention and treatment of heart failure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529483A JP2012529483A (ja) | 2012-11-22 |
| JP2012529483A5 JP2012529483A5 (https=) | 2013-07-18 |
| JP5689117B2 true JP5689117B2 (ja) | 2015-03-25 |
Family
ID=43308481
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514548A Expired - Fee Related JP5689117B2 (ja) | 2009-06-12 | 2010-06-11 | 心不全を防止及び治療するための組成物及び方法 |
| JP2012514554A Expired - Fee Related JP5892929B2 (ja) | 2009-06-12 | 2010-06-11 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
| JP2012514550A Expired - Fee Related JP5892928B2 (ja) | 2009-06-12 | 2010-06-11 | 赤血球凝固の予防及び治療のための組成物並びに方法 |
| JP2012514552A Expired - Fee Related JP5712207B2 (ja) | 2009-06-12 | 2010-06-11 | 脳疾患及び状態の予防及び治療のための組成物及び方法 |
| JP2012514549A Expired - Fee Related JP6076737B2 (ja) | 2009-06-12 | 2010-06-11 | 高血圧症の防止及び治療のための組成物並びに方法 |
| JP2012514551A Expired - Fee Related JP5827618B2 (ja) | 2009-06-12 | 2010-06-11 | 冠動脈性心疾患の予防及び治療のための組成物及び方法 |
| JP2015111092A Pending JP2015155468A (ja) | 2009-06-12 | 2015-06-01 | 赤血球凝固の予防及び治療のための組成物並びに方法 |
| JP2015124801A Pending JP2015164963A (ja) | 2009-06-12 | 2015-06-22 | 冠動脈性心疾患の予防及び治療のための組成物及び方法 |
| JP2015126506A Expired - Fee Related JP6187831B2 (ja) | 2009-06-12 | 2015-06-24 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
| JP2015126332A Pending JP2015164966A (ja) | 2009-06-12 | 2015-06-24 | 高血圧症の防止及び治療のための組成物並びに方法 |
| JP2017090148A Withdrawn JP2017128608A (ja) | 2009-06-12 | 2017-04-28 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
Family Applications After (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514554A Expired - Fee Related JP5892929B2 (ja) | 2009-06-12 | 2010-06-11 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
| JP2012514550A Expired - Fee Related JP5892928B2 (ja) | 2009-06-12 | 2010-06-11 | 赤血球凝固の予防及び治療のための組成物並びに方法 |
| JP2012514552A Expired - Fee Related JP5712207B2 (ja) | 2009-06-12 | 2010-06-11 | 脳疾患及び状態の予防及び治療のための組成物及び方法 |
| JP2012514549A Expired - Fee Related JP6076737B2 (ja) | 2009-06-12 | 2010-06-11 | 高血圧症の防止及び治療のための組成物並びに方法 |
| JP2012514551A Expired - Fee Related JP5827618B2 (ja) | 2009-06-12 | 2010-06-11 | 冠動脈性心疾患の予防及び治療のための組成物及び方法 |
| JP2015111092A Pending JP2015155468A (ja) | 2009-06-12 | 2015-06-01 | 赤血球凝固の予防及び治療のための組成物並びに方法 |
| JP2015124801A Pending JP2015164963A (ja) | 2009-06-12 | 2015-06-22 | 冠動脈性心疾患の予防及び治療のための組成物及び方法 |
| JP2015126506A Expired - Fee Related JP6187831B2 (ja) | 2009-06-12 | 2015-06-24 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
| JP2015126332A Pending JP2015164966A (ja) | 2009-06-12 | 2015-06-24 | 高血圧症の防止及び治療のための組成物並びに方法 |
| JP2017090148A Withdrawn JP2017128608A (ja) | 2009-06-12 | 2017-04-28 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US9283255B2 (https=) |
| EP (6) | EP2440209A4 (https=) |
| JP (11) | JP5689117B2 (https=) |
| CN (6) | CN102573865B (https=) |
| AU (11) | AU2010258356B2 (https=) |
| WO (6) | WO2010143059A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12397008B2 (en) * | 2006-04-13 | 2025-08-26 | Lead Billion Limited | Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries |
| AU2010258356B2 (en) | 2009-06-12 | 2017-01-19 | Generex Pharmaceuticals, Inc. | Compositions and methods for prevention and treatment of brain diseases and conditions |
| EP2655390B1 (en) * | 2010-12-23 | 2019-03-27 | Huya Bioscience International LLC | Purified cardiogenin isomer and related methods |
| JP6000521B2 (ja) * | 2011-08-10 | 2016-09-28 | 株式会社ブルボン | 血圧上昇抑制剤 |
| US10047034B2 (en) * | 2012-05-16 | 2018-08-14 | Prairie Berry Europe Gmbh | Polyhydroxylated pentacyclic triterpene acids as HMG-COA reductase inhibitors |
| US20140044813A1 (en) * | 2012-08-09 | 2014-02-13 | Kemin Industries, Inc. | Plant Extracts for Improving Cognitive Health and Function |
| CN103623753B (zh) * | 2013-11-27 | 2016-03-23 | 大兴安岭嘉迪欧营养原料有限公司 | 大兴安岭野生金老梅总三萜提取物的制备方法 |
| CN103623082B (zh) * | 2013-11-29 | 2016-08-17 | 江西中医药大学 | 覆盆子提取物及其应用 |
| US20150174057A1 (en) * | 2013-12-24 | 2015-06-25 | Generex Pharamaceutics Inc. | Compositions and methods for the prevention and treatment of oral diseases |
| JP2017507125A (ja) * | 2014-01-30 | 2017-03-16 | ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． | 認知機能を向上させるための植物抽出物 |
| CN105311030B (zh) * | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN104971091B (zh) * | 2015-06-03 | 2019-08-13 | 兴明生物医药技术(上海)有限公司 | 一种用于制备促进心肌再生药物的提取物的制备方法及其应用 |
| EP3325992B1 (en) | 2015-07-24 | 2026-01-28 | Northeastern University | Quantitative magnetic resonance imaging of the vasculature |
| CA2997659C (en) * | 2015-09-04 | 2023-08-01 | Reto ASMIS | Methods for treatment of monocyte dysfunction and chronic inflammatory micro- and macro-vascular diseases |
| CN105106222B (zh) * | 2015-09-14 | 2020-05-08 | 新乡医学院 | 吐曼酸在制备治疗或预防雌激素缺乏引起的阿尔茨海默病药物中的应用 |
| CN106581006B (zh) * | 2015-10-16 | 2019-11-29 | 香港理工大学深圳研究院 | 三萜类化合物在制备治疗帕金森药物中的应用 |
| CN106153761B (zh) * | 2016-06-07 | 2018-08-14 | 贵州师范大学 | 同时检测无籽刺梨果实中3种黄酮类成分的方法 |
| KR20190021344A (ko) | 2016-06-20 | 2019-03-05 | 버터플라이 네트워크, 인크. | 초음파 디바이스를 작동하는 사용자를 보조하기 위한 자동화된 영상 취득 |
| CN109562217A (zh) * | 2016-11-02 | 2019-04-02 | 天普大学-联邦高等教育体系 | 用于降低血液粘稠度、抑制血液循环中的乱流及治愈缗线状形成的系统及方法 |
| EP3615029A4 (en) * | 2017-04-25 | 2021-04-21 | Buck Institute for Research on Aging | FORMULATIONS TO EXTEND LIFE AND HEALTH |
| CN106946971A (zh) * | 2017-04-28 | 2017-07-14 | 南宁馨艺荣生物科技有限公司 | 一种从积雪草中提取积雪草酸的工艺 |
| CN107445855B (zh) * | 2017-08-07 | 2018-12-14 | 绍兴市逸晨医疗科技有限公司 | 一种盐酸多西环素杂质c的制备方法 |
| WO2019172174A1 (ja) * | 2018-03-05 | 2019-09-12 | 日本新薬株式会社 | Ｒａｇｅシグナル阻害作用をもつ食品素材 |
| KR20210035776A (ko) | 2018-03-06 | 2021-04-01 | 에피본, 인크. | 주사가능한 기성품 연골, 힘줄 및 인대 복구 조성물 및 사용 방법 |
| JP7365068B2 (ja) * | 2018-07-27 | 2023-10-19 | ノースイースタン ユニバーシティ | 血管磁気共鳴画像法による認知症の診断 |
| KR102152182B1 (ko) * | 2018-09-05 | 2020-09-04 | 한국식품연구원 | 큰뱀무 추출물을 유효성분으로 함유하는 우울 증상 또는 스트레스의 개선, 예방 또는 치료용 조성물 |
| JP7499259B2 (ja) | 2018-09-25 | 2024-06-13 | ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー | αケトグルタル酸カルシウムを製造するためのプロセス |
| CA3122592A1 (en) | 2018-12-21 | 2020-06-25 | Arlanxeo Singapore Pte. Ltd. | Halogen recovery in a wet process for halogenating unsaturated isoolefin copolymer |
| WO2020142696A1 (en) | 2019-01-03 | 2020-07-09 | Northeastern University | Quantitative measurement of disruptions in the blood brain barrier |
| CN109884222B (zh) * | 2019-01-17 | 2021-07-13 | 贵州中医药大学 | 一种小花清风藤的hplc指纹图谱建立方法 |
| KR102152174B1 (ko) * | 2020-03-30 | 2020-09-04 | 한국식품연구원 | 큰뱀무 추출물을 유효성분으로 함유하는 인지기능 장애의 개선, 예방 또는 치료용 조성물 |
| CN111643556A (zh) * | 2020-07-16 | 2020-09-11 | 杭州科倍安生物制药有限公司 | 一种用于预防和治疗痔疮的药物及其应用 |
| WO2022043407A1 (fr) | 2020-08-25 | 2022-03-03 | Laouarem Yousra | Compositions destinées au traitement des troubles neurologiques |
| KR102574207B1 (ko) * | 2020-12-03 | 2023-09-04 | 경북대학교 산학협력단 | 뱀무 추출물을 유효성분으로 하는 혈전성 질환 치료 또는 예방용 조성물 |
| CN112587599A (zh) * | 2021-01-11 | 2021-04-02 | 贵州中医药大学 | 一种预防急性高原反应的中药组合物 |
| CN112755079A (zh) * | 2021-01-18 | 2021-05-07 | 杭州科倍安生物制药有限公司 | 一种预防血栓形成或溶解已形成血栓的药物及其制备方法 |
| CN113367166B (zh) * | 2021-05-13 | 2022-07-26 | 海南大学 | 一种褐背蒲桃提取物杀菌剂及其制备方法和应用 |
| CN114028459A (zh) * | 2021-11-11 | 2022-02-11 | 杭州科贝生物制药有限公司 | 预防和治疗哺乳动物缺血性心脏病的药物和制备方法及应用 |
| CN114722066B (zh) * | 2022-03-23 | 2023-04-07 | 电子科技大学 | 一种预测材料自旋霍尔电导及反常霍尔电导的方法 |
| CN117257781A (zh) * | 2022-06-13 | 2023-12-22 | 上海市东方医院（同济大学附属东方医院） | 美金刚通过靶向心房心肌细胞谷氨酸受体有效干预房颤 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP2871763B2 (ja) * | 1989-12-15 | 1999-03-17 | 株式会社資生堂 | テストステロン―５α―レダクターゼ阻害剤 |
| CN1069629A (zh) | 1991-08-27 | 1993-03-10 | 段民生 | 一种康复面的制备方法 |
| CN1047089C (zh) * | 1992-12-03 | 1999-12-08 | 张斌 | 治疗近视眼的药物及制备工艺 |
| JPH07179347A (ja) * | 1993-12-21 | 1995-07-18 | Showa Shell Sekiyu Kk | 抗ウイルス組成物 |
| CN1102993A (zh) | 1993-12-21 | 1995-05-31 | 吴文才 | 多酶体系加工中草药的制剂方法 |
| US5589154A (en) | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| AU7580098A (en) * | 1997-05-15 | 1998-12-08 | University Of Washington | Composition and methods for treating alzheimer's disease and other amyloidoses |
| CN1176814A (zh) | 1997-06-26 | 1998-03-25 | 李静 | 预防和治疗脑血管病的口服液 |
| CN1102399C (zh) * | 2000-06-09 | 2003-03-05 | 张庆玉 | 降脂通脉胶囊 |
| US20030180395A1 (en) * | 2000-07-26 | 2003-09-25 | Bernd Bueter | Plant extract |
| WO2002009720A1 (en) * | 2000-07-31 | 2002-02-07 | University Of Virginia Patent Foundation | Inhibitors of dna polymerase sigma |
| US6629835B2 (en) | 2000-08-01 | 2003-10-07 | Metaproteomics, Llc | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
| JP2002255804A (ja) | 2001-03-02 | 2002-09-11 | Suntory Ltd | インシュリン様作用を有するヘキサオキシジフェン酸誘導体を含んでなる組成物 |
| WO2002078468A1 (fr) | 2001-03-30 | 2002-10-10 | The Nisshin Oillio, Ltd. | Aliment ou boisson pour maladie ou trouble vasculaire |
| KR100453569B1 (ko) * | 2001-09-11 | 2004-10-20 | 대한민국 | 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는항산화제 |
| JP2003201229A (ja) | 2001-10-23 | 2003-07-18 | Shiseido Co Ltd | マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料 |
| ATE481976T1 (de) | 2001-11-21 | 2010-10-15 | Univ Hong Kong Chinese | Zusammensetzungen aus organischen extrakten von geum japonicum thunb var. und ihre verwendung |
| JP4393777B2 (ja) * | 2002-03-19 | 2010-01-06 | 株式会社ファンケル | 抗ヘリコバクター・ピロリ用組成物 |
| US7387801B2 (en) | 2002-12-10 | 2008-06-17 | The Chinese University Of Hong Kong | Organic extract of Geum japonicum Thunb variant and use thereof |
| CN1239155C (zh) | 2003-01-23 | 2006-02-01 | 北京中医药大学 | 一种治疗缺血性脑中风的药物组合物及其制备方法 |
| US20040247698A1 (en) | 2003-06-04 | 2004-12-09 | Valenzuela Cortes Carmen Maria | Erectile Dysfunction Treatment |
| EP1677801A4 (en) | 2003-10-10 | 2010-09-22 | Sk Chemicals Co Ltd | EFFICIENT TRITERPENES TO IMPROVE BRAIN FUNCTIONS |
| CN1185007C (zh) | 2003-12-08 | 2005-01-19 | 张小朋 | 降脂溶栓药物 |
| CN100509008C (zh) | 2004-04-12 | 2009-07-08 | 赵晓昂 | 舒痛方及其制剂和用途 |
| WO2006054370A1 (en) | 2004-11-16 | 2006-05-26 | Use-Techno Corporation | Gluconeogenesis inhibiting agent |
| KR100704003B1 (ko) * | 2005-06-10 | 2007-04-06 | 안동대학교 산학협력단 | 2-알파-하이드록시-올레아놀산을 함유하는 트롬빈 저해혈전증 예방 및 치료용 조성물 |
| JP2006347967A (ja) | 2005-06-16 | 2006-12-28 | Yuusu Techno Corporation:Kk | 血糖値上昇抑制剤 |
| WO2007049088A1 (en) | 2005-10-27 | 2007-05-03 | Lead Billion Limited | Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues |
| WO2007049089A1 (en) * | 2005-10-27 | 2007-05-03 | Lead Billion Limited | Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues |
| DK1848440T3 (da) | 2005-10-27 | 2013-09-23 | Lead Billion Ltd | Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader |
| KR100718602B1 (ko) | 2005-12-29 | 2007-06-21 | 대한민국 | 항비만 및 항염증 효과를 가지는 뱀무 추출물, 이를포함하는 식품 조성물 및 이들의 제조 방법 |
| JP2007204447A (ja) | 2006-02-03 | 2007-08-16 | Yoshihiro Futamura | 中性脂肪減少作用を呈するカルニチン誘導体、それからなる抗肥満薬、食品製剤及びセルライト減少作用を呈する化粧品 |
| JP4731350B2 (ja) | 2006-02-17 | 2011-07-20 | 丸善製薬株式会社 | 抗老化剤、皮膚化粧料及び美容用飲食品 |
| AU2007225456B2 (en) | 2006-03-16 | 2013-03-28 | Moleac Pte Ltd | Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
| CN1857627B (zh) * | 2006-04-12 | 2010-05-19 | 贵阳利多药物技术开发有限公司 | 治疗中风的中药制剂及其制备方法 |
| US8821947B2 (en) | 2006-06-01 | 2014-09-02 | Howard W. Selby, III | Cholesterol-reducing diet |
| CN101091751A (zh) | 2006-06-22 | 2007-12-26 | 北京中医药大学 | 一种治疗高血压的中药组合物及其制备方法 |
| JP5281234B2 (ja) * | 2006-06-27 | 2013-09-04 | ポーラ化成工業株式会社 | 毛様体過緊張による疲れ目の改善・予防のための経口投与組成物 |
| CN100528195C (zh) * | 2006-06-28 | 2009-08-19 | 海南晨菲药业有限公司 | 一种大青根注射剂制备工艺 |
| CN101099770A (zh) | 2006-07-04 | 2008-01-09 | 北京中医药大学 | 一种具有咪唑啉受体激动活性的药物组合物及制备方法和应用 |
| JP2008074801A (ja) * | 2006-09-25 | 2008-04-03 | Oriza Yuka Kk | 肝保護剤 |
| JP5366358B2 (ja) * | 2006-09-29 | 2013-12-11 | 株式会社コーセー | 皮膚の老化機構に作用する剤、抗老化用皮膚外用剤、及び抗老化方法 |
| CN101040901A (zh) * | 2007-04-12 | 2007-09-26 | 云南龙润药业有限公司 | 迷迭香提取物及其制备方法和应用 |
| US9205112B2 (en) * | 2007-04-23 | 2015-12-08 | Creative Medical Health, Inc. | Combination treatment of cardiovascular disease |
| WO2008144706A2 (en) | 2007-05-21 | 2008-11-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Sweet gum fruit extract as a therapeutic agent |
| US20090022827A1 (en) | 2007-07-19 | 2009-01-22 | Ming Li | Agent and method for eliminating malignance of cancer cells without harmful effect to normal cells |
| CN101125171B (zh) * | 2007-08-20 | 2010-05-26 | 刘凤元 | 一种男、女补强中药 |
| KR100891881B1 (ko) * | 2007-08-23 | 2009-04-07 | 대한민국 | 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는고지혈증 및 ｍｍｐ 과다활성으로 인한 혈관질환 예방 및치료용 조성물 |
| CN101406537B (zh) | 2007-10-11 | 2013-05-15 | 首都医科大学 | 柔毛水杨梅提取物用于制备治疗肥胖的药物的用途 |
| CN101274012B (zh) * | 2008-01-23 | 2011-12-28 | 上海海天医药科技开发有限公司 | 夏枯草属植物提取物的组合物、制备方法及其药物用途 |
| AU2010258356B2 (en) * | 2009-06-12 | 2017-01-19 | Generex Pharmaceuticals, Inc. | Compositions and methods for prevention and treatment of brain diseases and conditions |
-
2010
- 2010-06-11 AU AU2010258356A patent/AU2010258356B2/en not_active Ceased
- 2010-06-11 AU AU2010258351A patent/AU2010258351B2/en not_active Ceased
- 2010-06-11 EP EP10785818A patent/EP2440209A4/en not_active Withdrawn
- 2010-06-11 CN CN201080026128.5A patent/CN102573865B/zh not_active Expired - Fee Related
- 2010-06-11 JP JP2012514548A patent/JP5689117B2/ja not_active Expired - Fee Related
- 2010-06-11 WO PCT/IB2010/001412 patent/WO2010143059A1/en not_active Ceased
- 2010-06-11 JP JP2012514554A patent/JP5892929B2/ja not_active Expired - Fee Related
- 2010-06-11 JP JP2012514550A patent/JP5892928B2/ja not_active Expired - Fee Related
- 2010-06-11 AU AU2010258355A patent/AU2010258355B2/en not_active Ceased
- 2010-06-11 US US13/377,489 patent/US9283255B2/en not_active Expired - Fee Related
- 2010-06-11 CN CN201080026141.0A patent/CN102711768B/zh not_active Expired - Fee Related
- 2010-06-11 EP EP10785822A patent/EP2440222A4/en not_active Withdrawn
- 2010-06-11 US US13/377,501 patent/US9629884B2/en not_active Expired - Fee Related
- 2010-06-11 WO PCT/IB2010/001418 patent/WO2010143063A1/en not_active Ceased
- 2010-06-11 JP JP2012514552A patent/JP5712207B2/ja not_active Expired - Fee Related
- 2010-06-11 AU AU2010258358A patent/AU2010258358B2/en not_active Ceased
- 2010-06-11 CN CN201080026126.6A patent/CN102740870B/zh not_active Expired - Fee Related
- 2010-06-11 JP JP2012514549A patent/JP6076737B2/ja not_active Expired - Fee Related
- 2010-06-11 CN CN201080030503.3A patent/CN102548560B/zh not_active Expired - Fee Related
- 2010-06-11 US US13/377,502 patent/US9950019B2/en active Active
- 2010-06-11 EP EP10785823A patent/EP2440223A4/en not_active Withdrawn
- 2010-06-11 CN CN201080026127.0A patent/CN102497873B/zh not_active Expired - Fee Related
- 2010-06-11 AU AU2010258354A patent/AU2010258354B2/en not_active Ceased
- 2010-06-11 JP JP2012514551A patent/JP5827618B2/ja not_active Expired - Fee Related
- 2010-06-11 EP EP10785820A patent/EP2440221A4/en not_active Withdrawn
- 2010-06-11 EP EP10785821A patent/EP2440212A4/en not_active Withdrawn
- 2010-06-11 CN CN201080030502.9A patent/CN102548571B/zh not_active Expired - Fee Related
- 2010-06-11 WO PCT/IB2010/001410 patent/WO2010143058A1/en not_active Ceased
- 2010-06-11 WO PCT/IB2010/001416 patent/WO2010143062A1/en not_active Ceased
- 2010-06-11 EP EP10785819A patent/EP2440220A4/en not_active Withdrawn
- 2010-06-11 WO PCT/IB2010/001415 patent/WO2010143061A1/en not_active Ceased
- 2010-06-11 WO PCT/IB2010/001426 patent/WO2010143065A1/en not_active Ceased
- 2010-06-11 US US13/377,498 patent/US20120148691A1/en not_active Abandoned
- 2010-06-11 AU AU2010258352A patent/AU2010258352B2/en not_active Ceased
- 2010-06-11 US US13/377,483 patent/US9050277B2/en not_active Expired - Fee Related
- 2010-06-11 US US13/377,503 patent/US20120077761A1/en not_active Abandoned
-
2015
- 2015-06-01 JP JP2015111092A patent/JP2015155468A/ja active Pending
- 2015-06-22 JP JP2015124801A patent/JP2015164963A/ja active Pending
- 2015-06-24 JP JP2015126506A patent/JP6187831B2/ja not_active Expired - Fee Related
- 2015-06-24 JP JP2015126332A patent/JP2015164966A/ja active Pending
-
2016
- 2016-03-09 AU AU2016201525A patent/AU2016201525A1/en not_active Abandoned
- 2016-04-27 AU AU2016202674A patent/AU2016202674A1/en not_active Abandoned
-
2017
- 2017-04-10 US US15/482,894 patent/US20180055896A1/en not_active Abandoned
- 2017-04-19 AU AU2017202572A patent/AU2017202572B2/en not_active Expired - Fee Related
- 2017-04-19 AU AU2017202573A patent/AU2017202573B2/en not_active Expired - Fee Related
- 2017-04-28 JP JP2017090148A patent/JP2017128608A/ja not_active Withdrawn
-
2018
- 2018-03-29 AU AU2018202291A patent/AU2018202291A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5689117B2 (ja) | 心不全を防止及び治療するための組成物及び方法 | |
| RU2486914C2 (ru) | Комбинированная терапия для лечения пациентов с неврологическими нарушениями и церебральным инфарктом | |
| US7438935B2 (en) | Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases | |
| EP3403664B1 (en) | Use of cistanche tubulosa | |
| Adewole et al. | Hypoglycaemic and hypotensive effects of Ficus exasperata Vahl.(Moraceae) leaf aqueous extracts in rats | |
| Hamburger et al. | Bryophyllum pinnatum–reverse engineering of an anthroposophic herbal medicine | |
| CN108186877A (zh) | 用于气虚血瘀证心肌梗死二级预防的中药组合物 | |
| CN113768956B (zh) | 无细胞脂肪提取液对巨噬细胞极化调节与疾病治疗的作用 | |
| CN109833320B (zh) | 人参皂苷在制备激活tmem16a离子通道的产品中的应用、激活剂、试剂盒和药物 | |
| US20180193401A1 (en) | Anti-obesity composition comprising natural complex | |
| KR100463263B1 (ko) | 골길이 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를 함유하는 약학적 제제 | |
| US11883452B2 (en) | Use of combination or composition of Radix et Rhizoma Notoginseng and aspirin | |
| RU2805492C1 (ru) | Способ коррекции постпрандиальной гликемии | |
| RU2805492C9 (ru) | Способ коррекции постпрандиальной гликемии | |
| RU2238755C1 (ru) | Лечебно-профилактическое средство, обладающее гепатопротекторным, холестерино- и сахарорегулирующим действием (варианты) | |
| JP2017114860A (ja) | 勃起不全改善及び血中テストステロン分泌増加のための組成物 | |
| CN1557416A (zh) | 一种治疗心血管疾病的药物制剂及其制备方法 | |
| Dadar et al. | Supplemental Effect of Zinc Oxide Nanoparticles and Prangos ferulacea Butanol Extract on Blood Glucose of Diabetic Wistar Rats. | |
| CN110664826A (zh) | 一种麦冬皂苷d’制剂及其降血糖药物新用途 | |
| CN110664825A (zh) | 一种麦冬皂苷d’制剂及其降血脂药物新用途 | |
| CN110664828A (zh) | 一种麦冬皂苷d制剂及其降血糖药物新用途 | |
| CN115252720B (zh) | 一种延缓心肌细胞衰老的益气活血养阴药物组合的制备方法及应用 | |
| KR100486968B1 (ko) | 누에 수번데기 건조엑스를 함유한 건강보조식품 조성물 | |
| HK40109146A (zh) | 一种多功效中药组合物、口服制剂及其制备方法和应用 | |
| CN118542924A (zh) | 一种多功效中药组合物、口服制剂及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130531 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140616 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140912 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140922 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141016 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150127 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5689117 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |